<table frame="border" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td colspan="2">
<content stylecode="bold">CYP2C19 or CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td>
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>Decreased exposure of omeprazole when used concomitantly with strong inducers <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#williamsonbk1196969546155">12.3</linkhtml>)]</content>.</td>
</tr>
<tr>
<td>
<content stylecode="italics">Intervention:</content>
</td>
<td>St. John’s Wort, rifampin: Avoid concomitant use with omeprazole <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#_6629fac6-0f05-b558-257e-cd2f203b648d">5.9</linkhtml>)]</content>. <br/>
<br/>Ritonavir-containing products: see prescribing information for specific drugs.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">CYP2C19 or CYP3A4 Inhibitors</content>
</td>
</tr>
<tr>
<td>
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>Increased exposure of omeprazole <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#williamsonbk1196969546155">12.3</linkhtml>)]</content>.</td>
</tr>
<tr>
<td>　 
                              <content stylecode="italics">Intervention:</content>
</td>
<td>Voriconazole: Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses, dose adjustment may be considered. <br/>
<br/>See prescribing information for voriconazole.</td>
</tr>
</tbody>
</table>